Press Releases

Circassia Interim Management Statement

Click here to download November 2014 Interim Management Statement – Strong operational progress; clinical programmes on track – – Encouraging results from third season follow-up study in grass allergy – Oxford, UK – 11 November...

View details

Interim Results for the Six Months Ended 30 June 2014

Click here to download the full 2014 interim results statement — Successfully raised over £200 million in landmark IPO — — Fully-funded to bring to market the first of a new generation of allergy immunotherapies...

View details

Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study

Click here to download full press release Oxford, UK – 13 June 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, today announces positive top-line results from a two-year...

View details

Notice of Interim Results

Oxford, UK – 3 June 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, will be announcing its interim results for the six months ended 30 June 2014 on...

View details

Interim management statement

May 2014 Interim Management Statement Oxford, UK – 19 May 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, today publishes its interim management statement for the period from...

View details

Circassia Appoints Paul R Edick to its Board of Directors

OXFORD, UK – 17 October 2013 – Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced the appointment of Paul R Edick to its Board.  Mr Edick is currently CEO of...

View details

Circassia’s Rapid Grass Allergy Treatment Achieves Significant Symptom Reduction During Hay Fever Season

OXFORD, UK – 1 October 2013 – Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced successful results from a large phase II clinical study of its ToleroMune® grass allergy treatment...

View details

Circassia Appoints Dr Francesco Granata as Chairman

OXFORD, UK – 25 September 2013 – Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced the appointment of Dr Francesco Granata as Non-Executive Chairman.  Dr Granata is Executive in Residence...

View details

Circassia’s Short-Course House Dust Mite Allergy Treatment Achieves Significant Long-Term Symptom Reduction

OXFORD, UK – 12 September 2013 – Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful results from a phase II clinical study of its house dust mite allergy treatment (House Dust...

View details

Circassia Initiates Proof-of-Principle Clinical Study for Novel Psoriasis Treatment

Circassia Ltd today announced that it has initiated a proof-of-principle clinical study of its novel topical psoriasis treatment, PAP-1. The phase Ib trial is designed to compare the efficacy of PAP-1 with the marketed psoriasis...

View details